Michelle Stacy
CIK 1448355 · President, U.S. Commercial · last filed 2024-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GMCR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WATERBURY, VT 05676
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IROBOT CORP (IRBT) Delisted | Director | 55,426 | $0.47 | $25.9K | -$969.9K | 17 | 2024-06-10 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Director | 103 | — | — | $24.9K | 5 | 2018-07-26 |
| KEURIG GREEN MOUNTAIN, INC. (GMCR) Delisted | President, U.S. Commercial | 11,655 | — | — | -$4.65M | 18 | 2013-05-15 |
Recent Filings · Page 2 of 4
40 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-08-23 | IROBOT CORP (IRBT) Delisted | Sell (S) | −1,500 | -$155.1K | EDGAR |
| 2018-07-26 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-12 | IROBOT CORP (IRBT) Delisted | Grant (A) | +1,868 | $0 | EDGAR |
| 2017-07-27 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-13 | IROBOT CORP (IRBT) Delisted | Grant (A) | +1,354 | $0 | EDGAR |
| 2016-06-14 | IROBOT CORP (IRBT) Delisted | Grant (A) | +2,923 | $0 | EDGAR |
| 2016-06-09 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-03-16 | IROBOT CORP (IRBT) Delisted | Buy (P) | +3,000 | $100.2K | EDGAR |
| 2016-03-16 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +2,585 | $24.9K | EDGAR |
| 2016-03-08 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.